Aurinia Pharmaceuticals Inc. (AUPH) Balance Sheet

The rise in equity appears driven primarily by retained earnings improvement, which is consistent with the profitability recovery visible in the prior income statement findings. This trajectory suggests the business is moving toward a more self-funded footing, though the accumulated deficit remains very large relative to current equity. Investors should monitor whether earnings persistence continues, since the reported quarterly swings noted earlier could reverse the trend.

Debt has declined from $86.0M in 2024Q2 to $58.7M, while equity expanded, so the leverage reduction appears to reflect both repayment and equity growth rather than either alone. The low leverage gives the company meaningful flexibility, though debt still represents a claim that cash flow must service. Refinancing exposure appears limited given the modest absolute balance, but the terms and maturity schedule are not included in the supplied data and warrant further review.

A current ratio above six implies that short-term obligations are well covered by current assets, but the ratio is inflated if a large share of those assets is non-cash. The sharp quarter-over-quarter cash drop suggests timing of receivables, payables, or capital deployment is influencing the buffer materially. Given the cash-flow findings showing lumpy buybacks, the liquidity cushion appears adequate today but sensitive to discretionary outflows.

The small PP&E base and negligible goodwill are consistent with a business model that relies on intangible or current assets rather than heavy capital investment. The gradual decline in PP&E from $108.2M in 2024Q2 suggests reduced capital spending or depreciation outpacing additions. The total asset base has grown substantially, so the composition of that growth, including its cash and receivables components, is central to judging asset quality.